Aktieanalyser från populära analyshus

Senaste aktieanalyserna

Devyser Q4: Initial take – good signs from Thermo Fisher partnership - Redeye

Analys | Redeye

•

13 Feb 11:27

Devyser Q4: Initial take – good signs from Thermo Fisher partnership - Redeye

Sivers Semiconductors: Strategic MOU Signals Continued AI Datacenter Momentum - Redeye

Redeye is encouraged by the new MOU, highlighting the shift from technology discussions to preparati...

Sivers Semiconductors

Analys | Redeye

•

13 Feb 11:27

Powercell Q4 2024: Solid numbers - Redeye

PowerCell

Analys | Analysguiden

•

13 Feb 11:27

Beijer Alma: Stabilt år trots svagare industrikonjunktur - Analysguiden

Beijer Alma levererar ett kvartal med både organisk och förvärvdriven tillväxt trots en svagare indu...

Sprint Bioscience Q4: Confident expansion - Redeye

Fortnox Q4: Roughly as Expected - Redeye

Redeye comments on Fortnox’s Q4 report, showing underlying numbers largely matching our expectations...

Nekkar Q4 2024: Slightly Above Expectations - Redeye

Acarix Q4 2024: Initial take – Soft revenues but good cost control - Redeye

Redeye provides its initial take on Acarix’s Q4 report, which showed revenues falling c32% short of ...

Acarix

Analys | Analysguiden

•

13 Feb 11:25

ExpreS2ion Biotech: Lovande start på nytt år - Analysguiden

SenzaGen Q4 Initial take – Soft sales but solid cost control - Redeye

Redeye provides an initial take following the release of SenzaGen’s Q4 2024 report.

Relais: Strong Q4 - intents to increase its M&A pace - Nordea

Stille Q4 2024: Initial take – Strong across the board despite impairment - Redeye

Redeye’s initial take on Stille’s year-end report is positive.

Optomed Q4: Initial take – Sales in line and slightly higher costs than expected - Redeye

Doro Q4 2024: Miss on topline but beat on profitability - Redeye

Redeye comments on Doro´s fourth quarter of the year.

Embracer Q3 2024/25: In line with preannounced numbers - Redeye

Thunderful Group Q4 2024: Sales better than expected - Redeye

Redeye comments on Thunderful Group’s Q4’24 report, which came in better than expected in terms of s...

Thunderful

Analys | ABG Sundal Collier

•

13 Feb 09:39

Eolus Vind: No big surprises, new targets for '25-'27 - ABG

Vibrosense Dynamics: Rapportkommentar Q2'24/25 - Kalqyl

VibroSense redovisade en nettoomsättning om 0,46 MSEK (0,57) i kvartalet, vilket var en minskning me...

Polygiene Group Q4 2024: Strong beat on both top-line and profitability - Redeye

CapMan: Solid underlying Q4 with boost from positive fair value changes - Nordea

CapMan’s underlying performance in Q4 was solid and slightly above our estimates.

CapMan

Analys | ABG Sundal Collier

•

13 Feb 09:31

Nilörngruppen: A long-awaited return to normal volumes - ABG

Xspray Pharma Q4 2024: In anticipation of an eventful year - Redeye

Redeye provides an update on Xspray Pharma following its year-end report, which revealed no major su...

G5 Entertainment Q4 2024: Solid year-end performance - Redeye

Atria: Soft Q4 and a negative guidance for 2025 - Nordea

Atria reported Q4 adjusted EBIT of EUR 13.2m, 19% (EUR 3.

Carasent Q4: Slightly Softer than Expected - Redeye

Neola Medical Q4: Vital clinical data incoming - Redeye

Redeye provides an update following Neola Medical’s Q4 2024 report.

Taaleri: Solid end to a turbulent year - Nordea

NoHo Partners: Breaking records even in a lower cycle - Nordea

NoHo Partners' Q4 2024 results came in clearly above Vara Research consensus, as the company continu...

Vertiseit: Integration and North America in Focus - Redeye

Vertiseit

Analys | ABG Sundal Collier

•

13 Feb 07:17

Medicover: Story continues, but without Mr Rågmark - ABG

Small beat in Q4 and news of CEO leaving Adj. EBITDA up 2.

Medicover

Föregående Nästa